ArriVent BioPharma, Inc. AVBP Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: ArriVent BioPharma, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s payments of stock issuance costs?
- ArriVent BioPharma, Inc. (AVBP) reported payments of stock issuance costs of $17K in Q4 2025.
- What does payments of stock issuance costs mean?
- This metric represents the direct cash outflows incurred by a company to facilitate the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. It serves as a measure of the friction costs associated with raising capital from public or private markets. Monitoring these costs helps investors assess the efficiency of the company's capital-raising activities and the impact of equity financing on net cash flows.